Document Detail

Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia.
MedLine Citation:
PMID:  10413068     Owner:  NLM     Status:  MEDLINE    
It has been reported that micronized fenofibrate and losartan can significantly decrease serum uric acid levels by augmenting uric acid excretion. We undertook this study to evaluate the effects of the combination treatment with micronized fenofibrate and losartan in nondiabetic hypertensive dyslipidemic patients with hyperuricemia (serum uric acid, >7 mg/ dl). A total of 25 patients (15 men, 10 women) aged 21-66 years was studied. In all patients, serum lipid parameters, including Lp(a), fibrinogen, and uric acid levels, as well as fractional excretion of uric acid (FEUA) were obtained before treatment, 8 weeks after micronized fenofibrate treatment (200 mg daily), and 8 weeks after combination therapy with micronized fenofibrate (200 mg daily) and losartan (50 mg daily). Fenofibrate alone significantly decreased total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, Apo B, Lp(a), fibrinogen, and uric acid levels (from 7.6+/-0.55 to 5.6 +/-0.5 mg/dl; p < 0.0001) and increased high-density lipoprotein (HDL) cholesterol, Apo A1, and FEUA (from 6.5+/-1.8% to 12.2+/-4%; p < 0.0001). The addition of losartan beyond the decrease in blood pressure values did not significantly alter serum metabolic parameters. However, a small additional decrease in serum uric acid levels (from 5.6+/-0.5 to 4.9+/-1 mg/dl; p < 0.05) was found because of a further increase in FEUA (from 12.2+/-4% to 14+/-5.5%; p < 0.05). It is concluded that the combination of micronized fenofibrate and losartan is useful for the management of patients with multiple metabolic abnormalities, including hyperuricemia.
M Elisaf; V Tsimichodimos; E Bairaktari; K C Siamopoulos
Related Documents :
8281718 - Diffusion kinetics of urea, creatinine and uric acid in blood during hemodialysis. clin...
870098 - Concentrations of adenine nucleotides in erythrocytes of patients with gout.
17445548 - 13c enrichment of carbons 2 and 8 of purine by folate-dependent reactions after [13c]fo...
9119628 - Biochemical relationship between urine composition and urinary stone formation in stone...
7358428 - Biological and chemical characterization of endotoxin from capnocytophaga sputigena.
17447468 - Saturated and monounsaturated fatty acids increase interleukin-10 production in rat hep...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  34     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1999 Jul 
Date Detail:
Created Date:  1999-10-14     Completed Date:  1999-10-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  60-3     Citation Subset:  IM    
Department of Internal Medicine, Medical School, University of Ioannina, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / administration & dosage,  pharmacology
Antilipemic Agents / administration & dosage,  pharmacology*
Blood Chemical Analysis
Hypertension / metabolism*
Losartan / administration & dosage,  pharmacology*
Middle Aged
Procetofen / administration & dosage,  pharmacology*
Uric Acid / blood,  metabolism*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Antilipemic Agents; 114798-26-4/Losartan; 49562-28-9/Procetofen; 69-93-2/Uric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A comparison of the binding characteristics of class I antiarrhythmic agents for human muscarinic m1...
Next Document:  Influence of FR 167653, an inhibitor of TNF-alpha and IL-1, on the cardiovascular responses to chron...